Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Summary

This phase I trial studies the side effects of stereotactic radiosurgery with MBG453 and spartalizumab in treating patients with recurrent glioblastoma multiforme (GBM). Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor to more precisely target the cancer. Monoclonal antibodies, such as MBG453 and spartalizumab may interfere with the ability of tumor cells to grow and spread. Giving stereotactic radiosurgery together with immunotherapy may be a better treatment for GBM.

Timeline

Start

2020-02-18

Primary completion

2022-11-16

Completion

2026-09

Drugs

Indications